VSTM Verastem Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VSTM

Price (delayed)

$3.885

Market cap

$341.39M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.4

Enterprise value

$261.07M

?
Relative Growth: Rel. Growth: 67
Relative Strength: Rel. Strength: 4
Relative Valuation: Rel. Valuation: 10
Relative Profitability: Rel. Profitability: 18

Verastem Oncology is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. The company's pipeline is focused on ...

Highlights
VSTM's gross profit has surged by 61% since the previous quarter
VSTM's revenue has surged by 60% since the previous quarter
VSTM's net income is down by 30% year-on-year but it is up by 7% since the previous quarter
Verastem's gross margin has decreased by 17% YoY
Verastem's quick ratio has decreased by 13% YoY and by 2.7% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.verastem.com
Peers: PFE CRIS LH

Key stats

What are the main financial stats of VSTM

VSTM stock price

How has the Verastem stock price performed over time
Intraday
7.32%
1 week
-9.44%
1 month
-34.71%
1 year
-37.03%
YTD
-49.68%
QTD
-26.7%

Financial performance

How have Verastem's revenue and profit performed over time
Revenue
$49.59M
Gross profit
$41.24M
Operating income
-$171.08M
Net income
-$193.96M
Gross margin
83.2%
Net margin
-391.2%
Verastem's operating margin has soared by 74% YoY and by 37% from the previous quarter
Verastem's net margin has soared by 74% YoY and by 42% from the previous quarter
VSTM's gross profit has surged by 61% since the previous quarter
VSTM's revenue has surged by 60% since the previous quarter

Price vs fundamentals

How does VSTM's price correlate with its fundamentals

Growth

What is Verastem's growth rate over time

Valuation

What is Verastem stock price valuation
P/E
N/A
P/B
4.17
P/S
7.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.27
Verastem's EPS has increased by 30% YoY and by 21% QoQ
Verastem's equity has increased by 43% QoQ
The stock's P/B is 25% below its 5-year quarterly average of 5.2
The price to sales (P/S) is 86% lower than the last 4 quarters average of 51.1
VSTM's revenue has surged by 60% since the previous quarter

Efficiency

How efficient is Verastem business performance
Verastem's return on equity has surged by 74% QoQ
Verastem's return on sales has surged by 73% YoY and by 42% QoQ
The ROA has grown by 28% YoY and by 18% from the previous quarter
The ROIC has grown by 17% YoY and by 12% from the previous quarter

Dividends

What is VSTM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VSTM.

Financial health

How did Verastem financials performed over time
The total assets is 56% greater than the total liabilities
The total assets has surged by 73% year-on-year but it has declined by 8% since the previous quarter
Verastem's total liabilities has decreased by 23% from the previous quarter and by 11% YoY
Verastem's debt is 4.5% more than its equity
VSTM's debt to equity has surged by 144% year-on-year but it is down by 31% since the previous quarter
Verastem's equity has increased by 43% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.